In yesterday’s Wall Street session, Gilead Sciences, Inc. (NASDAQ:GILD) shares traded at $75.23, up 0.97% from the previous session.
As of this writing, 32 analysts cover Gilead Sciences, Inc. (NASDAQ:GILD). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $116.00 and a low of $71.00, we find $90.10. Given the previous closing price of $74.51, this indicates a potential upside of 20.92 percent. GILD stock price is now -1.86% away from the 50-day moving average and -4.18% away from the 200-day moving average. The market capitalization of the company currently stands at $93.74B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
There are 15 analysts who have given it a hold rating, whereas 14 have given it a buy rating. Brokers who have rated the stock have averaged $89.82 as their price target over the next twelve months.
With the price target of $75, Deutsche Bank recently initiated with Hold rating for Gilead Sciences, Inc. (NASDAQ: GILD).
In other news, Dickinson Andrew D, Chief Financial Officer sold 5,000 shares of the company’s stock on Oct 17. The stock was sold for $400,017 at an average price of $80.00. Upon completion of the transaction, the Chief Financial Officer now directly owns 104,003 shares in the company, valued at $7.82 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 12, Chief Medical Officer Parsey Merdad sold 1,501 shares of the business’s stock. A total of $115,562 was realized by selling the stock at an average price of $76.99. This leaves the insider owning 70,130 shares of the company worth $5.28 million. Insiders disposed of 218,077 shares of company stock worth roughly $16.41 million over the past 1 year. A total of 0.08% of the company’s stock is owned by insiders.
During the past 12 months, Gilead Sciences, Inc. has had a low of $72.87 and a high of $89.74. As of last week, the company has a debt-to-equity ratio of 1.12, a current ratio of 1.34, and a quick ratio of 1.20. According to the stock market information, the enterprise value for the company is $110.96B, which is based on a 16.13 price-to-earnings ratio, a 3.91 price-to-earnings-growth ratio, and a beta of 0.30. The fifty day moving average price for GILD is $76.64 and a two-hundred day moving average price translates $78.45 for the stock.
The latest earnings results from Gilead Sciences, Inc. (NASDAQ: GILD) was released for Sep, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $2.29, beating analysts’ expectations of $1.92 by 0.37. This compares to $1.42 EPS in the same period last year. The net profit margin was 21.55% and return on equity was 27.08% for GILD. The company reported revenue of $7.05 billion for the quarter, compared to $7.04 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.13 percent. For the current quarter, analysts expect GILD to generate $7.08B in revenue.
Gilead Sciences, Inc.(GILD) Company Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.
